Slide 1: FDA Approval YUTREPIA (treprostinil) inhalation powder Investor Call
FDA Approval YUTREPIA (treprostinil) inhalation powder Investor Call May 27, 2025 ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED
Slide 2: Forward-looking statements
Forward-looking statements This presentation includes, and our response to questions may include, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). All statements contained in this presentation other than statements of historical facts,
Slide 3: Now FDA Approved
Now FDA Approved ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED 3
Slide 4: Please see Important Safety Information throughout and Full Prescribing Information
Please see Important Safety Information throughout and Full Prescribing Information available at this presentation.
Slide 5: Bringing a new choice to address unmet needs
Bringing a new choice to address unmet needs PAH PH-ILD 45,000 patients treated 60,000 + patients prevalent 18,000 new to prostacyclin Only 6,000 treated since 2021 or needing better choices PAH: Pulmonary Arterial Hypertension, PH-ILD: Pulmonary Hypertension with Interstitial Lung Disease ©2025 LIQ
Slide 6: YUTREPIA offers a new choice to treat PAH & PH-ILD
YUTREPIA offers a new choice to treat PAH & PH-ILD Highlights of Prescribing Information Prescribing Information and Instructions for Use for YUTREPIA (treprostinil) inhalation powder are available at YUTREPIA.com ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED 6
Slide 7: Enables wide range of dosing for naïve and transition patients
Enables wide range of dosing for naïve and transition patients Transitioning from Treprostinil Inhalation Solution Adverse Reactions from INSPIRE Study in PAH patients1 Tyvaso® Dose YUTREPIA (treprostinil) inhalation powder Transitions Naïve Occurring in n=55 n=66 Breaths per session Dose (mcg) Caps
Slide 8: YUTREPIA is taking titration to a whole new level
YUTREPIA is taking titration to a whole new level ASCENT study data n= first 20 PH-ILD patients treated for 8 weeks Patients achieve tolerable doses quickly Median Dosing at Week 8 was 132.5 mcg1 • No dose dependent AEs 265.0 30 bps • Most frequent TEAE is cough, all mild n=18 Tyvaso® breaths per se
Slide 9: Offering patient access and choice with full support services
Offering patient access and choice with full support services WAC price for 28-day supply is $24,360 and at parity with Tyvaso DPI® Patient Voucher Co-Pay Bridge Assistance Program Program Program Program Starter Kit Full Patient Support Services Reimbursement Patient in-home Patient start Follow-up
Slide 10: Commercial team is fully mobilized and will start detailing today!
Commercial team is fully mobilized and will start detailing today! Field Force 140 60 10 Commercial Medical targeting calling on Specialty Centers 6,500 Team Science Liaisons Physicians Field Reimbursement Treating PH, ILD or Both 650 Specialists Community Accounts PH: Pulmonary Hypertension, ILD: I
Slide 11: Determined to become the prostacyclin of first choice
Determined to become the prostacyclin of first choice • PAH & PH-ILD Approved • Deep Lung Delivery, Device, Dose • Detailing physicians nationwide Prepared • Available in ~14 days • Broad market access Accessible • Full suite of patient support services ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED
Slide 12: Q&A
Q&A Dr. Roger Jeffs Scott Moomaw Chief Executive Officer Chief Commercial Officer Michael Kaseta Rajeev Saggar COO & CFO Chief Medical Officer Russell Schundler Jason Adair General Counsel Chief Business Officer ©2025 LIQUIDIA CORPORATION ALL RIGHTS RESERVED 12